Short Interest in Lisata Therapeutics, Inc. (NASDAQ:LSTA) Declines By 56.6%

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the target of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 56,341 shares, a decrease of 56.6% from the July 15th total of 129,920 shares. Approximately 0.7% of the company’s shares are sold short. Based on an average daily volume of 155,428 shares, the short-interest ratio is currently 0.4 days.

Lisata Therapeutics Trading Down 3.5%

NASDAQ LSTA traded down $0.04 during trading hours on Friday, hitting $1.09. 24,983 shares of the company’s stock were exchanged, compared to its average volume of 128,470. The stock has a 50-day simple moving average of $2.64 and a 200 day simple moving average of $3.63. Lisata Therapeutics has a 1-year low of $0.99 and a 1-year high of $5.07.

Institutional Trading of Lisata Therapeutics

Several large investors have recently modified their holdings of the stock. Cerity Partners LLC acquired a new stake in shares of Lisata Therapeutics during the 2nd quarter worth approximately $32,000. CIBC Bancorp USA Inc. acquired a new position in shares of Lisata Therapeutics during the 3rd quarter valued at $37,000. SOL Capital Management CO acquired a new position in shares of Lisata Therapeutics during the 1st quarter valued at $61,000. Ground Swell Capital LLC boosted its stake in Lisata Therapeutics by 64.0% during the fourth quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock worth $73,000 after acquiring an additional 15,213 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Lisata Therapeutics during the second quarter worth $157,000. Institutional investors and hedge funds own 8.94% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on LSTA. Zacks Research raised Lisata Therapeutics to a “hold” rating in a report on Monday, May 18th. HC Wainwright cut Lisata Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 15th. Finally, Weiss Ratings downgraded Lisata Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 31st. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Lisata Therapeutics currently has an average rating of “Reduce” and a consensus target price of $15.00.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.